Enlivex Ltd. (ENLV) 股票分析

公司概述

Enlivex Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company headquartered in Israel, specializing in the development of cell therapies designed to restore macrophage homeostasis. The company is positioned within the broader Healthcare sector, specifically focusing on the Biotechnology industry, which implies a high-risk, high-reward profile characterized by significant research and development expenditures before potential commercialization. Currently, Enlivex Ltd. maintains a market capitalization of $227.26M and employs a workforce of 34 individuals to advance its pipeline, which includes the AllocetraTM intra-articular injection for the treatment of knee osteoarthritis. The combination of a market cap exceeding two hundred million dollars while reporting N/A for annual revenue indicates that the company is in an early-stage growth phase where valuation is driven by asset potential rather than established cash flow generation, reflecting its position as a pre-revenue biotechnology entity.

财务健康

The financial statements for Enlivex Ltd. show a Net Income (TTM) of $1.24B and an EBITDA of $-14,668,000, while Revenue (TTM) is listed as N/A; this divergence reveals a complex accounting reality where reported net income may include non-operating gains or adjustments that obscure the fundamental operational burn rate typical of clinical-stage firms. The company reports a Free Cash Flow of $-1,737,054,976, indicating a substantial cash outflow that limits immediate financial flexibility and necessitates continuous capital raising to sustain operations. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, suggesting that at this stage, the company has not yet generated commercial sales sufficient to calculate standard profitability ratios or that costs are entirely absorbed before revenue recognition. In terms of leverage, the company holds $5.75M in cash against $641,000 in debt, resulting in a Debt to Equity ratio of 0.03, which portrays a highly conservative balance sheet with negligible debt obligations relative to equity. Liquidity is robust as evidenced by a Current Ratio of 193.24, indicating that the company possesses more than enough current assets to cover its short-term liabilities without immediate distress. Return on Equity stands at 126.2% while Return on Assets is -0.8%, a metric combination that suggests management is leveraging equity heavily, likely through share dilution or specific accounting treatments, to amplify returns despite the negative asset-level performance common in asset-heavy biotech development cycles.

估值评估

Valuation metrics for Enlivex Ltd. present a P/E Ratio (TTM) of 0.04 and a Forward P/E of -1.22, a discrepancy that implies the market is pricing in a transition period where future earnings are projected to be negative or negligible compared to the current distorted trailing earnings figure. The Price to Book ratio is 0.12, indicating that the market values the company's equity at a fraction of its book value, which is typical for clinical-stage biotechs where the market discounts current assets to account for the time-to-value of the R&D pipeline. Alternative valuation multiples such as Price to Sales (N/A) and EV/EBITDA (-15.02) further illustrate the lack of traditional revenue-based valuation and a negative enterprise value relative to earnings, reflecting the speculative nature of the asset. The stock trades within a 52-week range bounded by a high of $2.10 and a low of $0.66; without a specific current price provided in the facts, the valuation is anchored to this volatility band where the market cap of $227.26M fluctuates based on these price extremes. The Beta of 1.68 signifies that the stock exhibits significantly higher price volatility relative to the broader market, moving 68% more aggressively than the index, which increases the risk premium required by investors.

Growth & Income

Enlivex Ltd. reports N/A for both Revenue Growth (YoY) and Earnings Growth (YoY), reflecting the fact that the company has not yet reached a stage of consistent commercial growth where year-over-year comparisons are statistically meaningful for traditional biotechnology metrics. The company does not pay dividends, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, which confirms that all available earnings and cash reserves are being reinvested directly into research and development activities rather than distributed to shareholders. This reinvestment strategy is standard for clinical-stage firms attempting to bridge the gap between current cash levels of $5.75M and the substantial cash burn required to complete clinical trials and regulatory approval. Consequently, the overall growth and income profile is defined by capital appreciation potential derived from the successful progression of the AllocetraTM therapy rather than income generation, leaving investors exposed to binary outcomes based on the efficacy of the immunotherapy platform.